home / stock / cmmb / cmmb quote
Last: | $0.969 |
---|---|
Change Percent: | 0.0% |
Open: | $0.9419 |
Close: | $0.969 |
High: | $0.9701 |
Low: | $0.9101 |
Volume: | 13,900 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.969 | $0.9419 | $0.969 | $0.9701 | $0.9101 | 13,900 | 07-03-2024 |
$0.969 | $0.99 | $0.969 | $0.99 | $0.9188 | 5,366 | 07-02-2024 |
$0.966 | $0.9125 | $0.966 | $0.98 | $0.9125 | 38,269 | 07-01-2024 |
$0.912499 | $0.97 | $0.912499 | $1.01 | $0.9 | 69,584 | 06-28-2024 |
$0.971001 | $0.975 | $0.971001 | $1.0196 | $0.9501 | 32,588 | 06-27-2024 |
$1 | $1.0201 | $1 | $1.0299 | $0.98 | 50,159 | 06-26-2024 |
$1.0245 | $0.99 | $1.0245 | $1.0675 | $0.9503 | 96,396 | 06-25-2024 |
$0.9988 | $0.96 | $0.9988 | $1.015 | $0.9158 | 63,387 | 06-24-2024 |
$0.93 | $0.9 | $0.93 | $0.9555 | $0.8901 | 22,826 | 06-21-2024 |
$0.93 | $0.95 | $0.93 | $0.9975 | $0.9 | 74,337 | 06-20-2024 |
$0.948 | $0.9441 | $0.948 | $1.035 | $0.9 | 169,073 | 06-19-2024 |
$0.948 | $0.9441 | $0.948 | $1.035 | $0.9 | 169,073 | 06-18-2024 |
$0.8499 | $1.13 | $0.8499 | $1.13 | $0.780101 | 321,870 | 06-17-2024 |
$1.13 | $1.16 | $1.13 | $1.2 | $1.0901 | 68,246 | 06-14-2024 |
$1.15 | $1.14 | $1.15 | $1.19 | $1.08 | 43,991 | 06-13-2024 |
$1.095 | $1 | $1.095 | $1.095 | $1 | 75,242 | 06-12-2024 |
$0.9999 | $0.9798 | $0.9999 | $1.0899 | $0.9798 | 9,179 | 06-11-2024 |
$0.9996 | $1.0499 | $0.9996 | $1.0499 | $0.9521 | 41,505 | 06-10-2024 |
$1.02 | $1.07 | $1.02 | $1.1 | $0.95 | 132,623 | 06-07-2024 |
$1.1399 | $1.27 | $1.1399 | $1.27 | $1.09 | 144,154 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Chemomab Therapeutics Ltd. Company Name:
CMMB Stock Symbol:
NASDAQ Market:
Chemomab Therapeutics Ltd. Website:
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— ...
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational Data Further Confirms CM-101’s ...